A new combination of drugs could help delay the advancement of a deadly form of prostate cancer in those with an advanced form of the disease, new research has found. The "striking" findings showed an ...

New research in JNCCN—Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate cancer later in life, and treated according to NCCN ...

Black men choose aggressive prostate cancer treatment—regardless of anticipated life expectancy—more often than Hispanic or Caucasian men, according to new research by Cedars-Sinai investigators ...

Men treated for nonmetastatic prostate cancer under current guidelines are up to 6 times less likely to die from their cancer than from other causes, according to data from a Swedish cancer registry.

New research in the July 2025 issue of JNCCN-Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate cancer later in life, and treated ...

Patients with nonmetastatic prostate cancer are more likely to die from other causes than from cancer when treated per guidelines. The 15-year cancer mortality risk is 5.5% for low-risk and 22% for ...

Risk of death and cause of death 30 years after diagnosis as a proportion of 100 men. Grey figures indicate the proportion of men alive after 30 years, blue figures the proportion of men who died of ...

Prostate cancer screening would save thousands of lives, a landmark study has revealed. A national programme would save one life for every 500 men tested, according to the most comprehensive analysis ...

Former President Joe Biden and other older men may not be getting routine prostate cancer screenings but his recent Stage 4 diagnosis raises questions about whether that's always the best choice.